• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ORTHO-CLINICAL DIAGNOSTICS VITROS IMMUNODIAGNOSTIC PRODUCTS BHCG II REAGENT PACK; IN-VITRO DIAGNOSTIC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ORTHO-CLINICAL DIAGNOSTICS VITROS IMMUNODIAGNOSTIC PRODUCTS BHCG II REAGENT PACK; IN-VITRO DIAGNOSTIC Back to Search Results
Catalog Number 6802220
Device Problem Incorrect Or Inadequate Test Results (2456)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 02/02/2017
Event Type  malfunction  
Manufacturer Narrative
The investigation has determined that a non-reproducible, higher than expected vitros bhcg result was obtained from a single patient sample on a vitros eciq immunodiagnostic system.The definitive assignable cause could not be determined, however, based on condition codes indicating the lis and vitros system were not communicating, and multiple condition codes for sample mismatch and program issues, pre-analytical sample mix up cannot be ruled out as contributing to the event, although this could not be confirmed.Based on historical quality control results and vitros bhcg within-run precision testing, there was no indication the vitros bhcg reagent or the vitros eciq system malfunctioned.Additionally, it was unknown if the affected patient sample was centrifuged according to the sample device manufacturer¿s recommendations, therefore, improper pre-analytical sample processing cannot be ruled out as contributing to the event.It is possible that cellular debris, due to poor sample preparation, was present in the affected samples, although this could not be confirmed.A definitive assignable cause for the event could not be determined.
 
Event Description
A customer obtained a non-reproducible, higher than expected, vitros bhcg result from a single patient sample when processed on a vitros eciq immunodiagnostic system.Patient sample result of 79.1 miu/ml versus < 2.39 miu/ml.Biased results of the direction and magnitude observed may lead to inappropriate physician action.The non-reproducible, higher than expected vitros bhcg results was not reported outside of the laboratory and there was no report of actual patient harm as a result of this event.(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VITROS IMMUNODIAGNOSTIC PRODUCTS BHCG II REAGENT PACK
Type of Device
IN-VITRO DIAGNOSTIC
Manufacturer (Section D)
ORTHO-CLINICAL DIAGNOSTICS
100 indigo creek drive
rochester NY 14626
Manufacturer (Section G)
ORTHO CLINICAL DIAGNOSTICS
felindre meadows
pencoed
bridgend, wales CF35 5PZ
UK   CF35 5PZ
Manufacturer Contact
james a stevens
100 indigo creek drive
rochester, NY 14626
5854533000
MDR Report Key6375397
MDR Text Key69280864
Report Number3007111389-2017-00024
Device Sequence Number1
Product Code DHA
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,o
Reporter Occupation Other
Type of Report Initial
Report Date 03/03/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/03/2017
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date08/11/2017
Device Catalogue Number6802220
Device Lot Number1738
Other Device ID Number10758750002320
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? No
Date Manufacturer Received02/06/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured09/12/2016
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
-
-